|
| Author | Journal | Comparison | Number of randomised patients | Construct | Selective
outcome reporting | Outcome | Number of patients | Standard mean differences (SMD) measured as Cohens’ d (SE) | Rank of responsiveness measured as SMD |
|
Altman et al. (Flexx)
2009 | Semin Arthritis Rheum. | Sodium hyaluronate versus saline | 588 | Pain | Unclear | WOMAC | 291/295 | 0.143 (0.083) | 2 |
| | | | | | VAS (walking) | 285/295 | 0.259 (0.083) | 1 |
| | | | | | WOMAC | 291/295 | 0.194 (0.083) | 1 |
| | | | Disability | | SF-36 (PCS) | 291/295 | 0.191 (0.083) | 2 |
| | | | | | SF-36 (PF) | 291/295 | 0.170 (0.083) | 3 |
Baltzer et al.
2009 | Osteoarthritis and Cartilage | Autologous conditioned serum (ACS) versus saline | 241 | Pain | Unclear | WOMAC | 134/107 | 0.703 (0.166) | 2 |
| | | | | | VAS (activity) | 134/107 | 0.937 (0.169) | 1 |
| | | | Disability | | WOMAC | 134/107 | 0.699 (0.166) | 1 |
| | | | | | SF-8 (PCS) | 134/107 | 0.682 (0.166) | 2 |
| | Hyaluronan versus saline | 242 | Pain | Unclear | WOMAC | 135/107 | 0.050 (0.162) | 1 |
| | | | | | VAS (activity) | 135/107 | 0.035 (0.162) | 2 |
| | | | Disability | | WOMAC | 135/107 | 0.078 (0.162) | 2 |
| | | | | | SF-8 (PCS) | 135/107 | 0.146 (0.162) | 1 |
Barthel et al.
2009 | Semin Arthritis Rheum. | Diclofenac versus vehicle | 492 | Pain | Unclear | WOMAC | 254/238 | 0.234 (0.091) | 2 |
| | | | | | VAS (activity) | 254/238 | 0.281 (0.091) | 1 |
Bennell et al.
2005 | Ann. Rheum. Dis. | Multimodal physiotherapy programme versus placebo | 140 | Pain | Unclear | WOMAC | 73/67 | 0.122 (0.169) | 3 |
| | | | | | VAS (activity) | 73/67 | 0.223 (0.170) | 1 |
| | | | | | SF-36 (BP) | 73/67 | 0.071 (0.169) | 4 |
| | | | | | VAS (knee) | 73/67 | 0.216 (0.170) | 2 |
| | | | Disability | | WOMAC | 73/67 | 0.085 (0.169) | 2 |
| | | | | | SF-36 (PF) | 73/67 | 0.236 (0.170) | 1 |
Berman et al.
2004 | Ann. Intern. Med. | Acupuncture versus sham acupuncture | 381 | Disability | Unclear | WOMAC | 142/141 | 0.201 (0.146) | 1 |
| | | | | | SF-36 (PCS) | 142/141 | 0.134 (0.146) | 2 |
| | Education versus sham acupuncture | 380 | Disability | Unclear | WOMAC | 141/108 | −0.244 (0.154) | 2 |
| | | | | | SF-36 (PCS) | 141/108 | −0.255 (0.154) | 1 |
Burch et al.
2008 | Osteoarthritis and Cartilage | Pattern stimulation versus control (TENS) | 116 | Pain | Unclear | WOMAC | 52/53 | 0.698 (0.201) | 1 |
| | | | | | VAS (global) | 52/53 | 0.231 (0.195) | 2 |
Case et al.
2003 | Ann. Intern. Med. | Diclofena versus placebo | 53 | Pain | Unclear | WOMAC | 25/28 | 0.446 (0.338) | 1 |
| | | | | | Lequesne | 25/28 | 0.190 (0.334) | 2 |
| | Acetaminophen versus placebo | 57 | Pain | Unclear | WOMAC | 29/28 | 0.096 (0.326) | 2 |
| | | | | | Lequesne | 29/28 | 0.217 (0.326) | 1 |
Clegg et al.
2006 | N. Engl. J. Med. | Glucosamine + chondroitin versus placebo | 630 | Pain | Inadequate | WOMAC | 317/313 | 0.127 (0.126) | 2 |
| | | | | | HAQ | 317/313 | 0.146 (0.126) | 1 |
| | | | Disability | | WOMAC | 317/313 | 0.137 (0.126) | 1 |
| | | | | | HAQ | 317/313 | 0.104 (0.126) | 2 |
| | Glucosamine versus placebo | 630 | Pain | Inadequate | WOMAC | 317/313 | −0.028 (0.126) | 1 |
| | | | | | HAQ | 317/313 | −0.021 (0.126) | 2 |
| | | | Disability | | WOMAC | 317/313 | −0.013 (0.126) | 2 |
| | | | | | HAQ | 317/313 | 0.056 (0.126) | 1 |
| | Chondroitin versus placebo | 631 | Pain | Inadequate | WOMAC | 318/313 | −0.020 (0.126) | 2 |
| | | | | | HAQ | 318/313 | −0.046 (0.126) | 1 |
| | | | Disability | | WOMAC | 318/313 | 0.023 (0.126) | 2 |
| | | | | | HAQ | 318/313 | 0.029 (0.126) | 1 |
| | Celecoxib versus placebo | 631 | Pain | Inadequate | WOMAC | 318/313 | 0.132 (0.126) | 1 |
| | | | | | HAQ | 318/313 | 0.130 (0.126) | 2 |
| | | | Disability | | WOMAC | 318/313 | 0.179 (0.126) | 1 |
| | | | | | HAQ | 318/313 | 0.114 (0.126) | 2 |
Forestier et al.
2009 | Ann. Rheum. Dis. | Spa therapy versus control | 451 | Pain | Adequate | VAS (knee) | 193/186 | 0.310 (0.103) | 1 |
| | | | | | SF-36 (BP) | 194/185 | 0.190 (0.103) | 2 |
| | | | Disability | | WOMAC | 179/172 | 0.366 (0.108) | 1 |
| | | | | | SF-36 (PCS) | 190/177 | 0.153 (0.105) | 2 |
| | | | | | SF-36 (PF) | 195/186 | 0.070 (0.103) | 3 |
Geba et al.
2002 | JAMA | Rofecoxib 25 mg/d versus acetaminophen | 189 | Pain | Inadequate | VAS (walking) | 95/94 | 0.467 (0.208) | 1 |
| | | | | | VAS (night) | 95/94 | 0.394 (0.207) | 3 |
| | | | | | VAS (rest) | 95/94 | 0.411 (0.206) | 2 |
| | Rofecixib 12.5 mg/d versus acetaminophen | 190 | Pain | Inadequate | VAS (walking) | 96/94 | 0.191 (0.206) | 1 |
| | | | | | VAS (night) | 96/94 | 0.069 (0.206) | 3 |
| | | | | | VAS (rest) | 96/94 | 0.135 (0.206) | 2 |
| | Celecoxib versus Acetaminophen | 191 | Pain | Inadequate | VAS (walking) | 97/94 | 0.233 (0.206) | 1 |
| | | | | | VAS (night) | 97/94 | −0.043 (0.206) | 3 |
| | | | | | VAS (rest) | 97/94 | 0.074 (0.206) | 2 |
Gibofsky et al.
2003 | Arthritis, Rheum. | Rofecoxib versus placebo | 285 | Pain | Unclear | WOMAC | 189/96 | 0.489 (0.163) | 1 |
| | | | | | VAS (walking) | 189/96 | 0.366 (0.162) | 2 |
| | Celecoxib versus placebo | 286 | Pain | Unclear | WOMAC | 190/96 | 0.514 (0.163) | 1 |
| | | | | | VAS (walking) | 190/96 | 0.451 (0.163) | 2 |
Hinman et al.
2003 | BMJ | Tappening versus placebo | 58 | Pain | Unclear | WOMAC | 29/29 | 0.160 (0.318) | 4 |
| | | | | | NRS (activity) | 29/29 | 0.802 (0.329) | 1 |
| | | | | | NRS (walking) | 29/29 | 0.795 (0.329) | 2 |
| | | | | | SF-36 (BP) | 29/29 | 0.308 (0.320) | 3 |
| | | | Disability | | WOMAC | 29/29 | 1.019 (0.340) | 1 |
| | | | | | SF-36 (PF) | 29/29 | 0.247 (0.323) | 2 |
| | Control tape versus placebo | 58 | Pain | Unclear | WOMAC | 29/29 | 0.649 (0.329) | 1 |
| | | | | | NRS (activity) | 29/29 | 0.376 (0.329) | 4 |
| | | | | | NRS (walking) | 29/29 | 0.649 (0.329) | 1 |
| | | | | | SF-36 (BP) | 29/29 | 0.431 (0.325) | 3 |
| | | | Disability | | WOMAC | 29/29 | 0.640 (0.329) | 1 |
| | | | | | SF-36 (PF) | 29/29 | 0.230 (0.323) | 2 |
Hughes and Carr
2002 | Rheumatology | Glucosamine sulphate versus placebo | 80 | Pain | Unclear | WOMAC | 39/39 | −0.066 (0.227) | 3 |
| | | | | | VAS (activity) | 39/39 | −0.020 (0.226) | 5 |
| | | | | | VAS (knee) | 39/39 | −0.032 (0.226) | 4 |
| | | | | | VAS (rest) | 39/39 | 0.323 (0.228) | 1 |
| | | | | | McGill (sense) | 39/39 | 0.221 (0.227) | 2 |
Kirkley et al.
2008 | N. Engl. J. Med. | Arthroscopic surgery versus placebo | 188 | Pain | Adequate | WOMAC | 88/80 | 0.316 (0.155) | 1 |
| | | | | | ASES | 88/80 | −0.073 (0.155) | 2 |
| | | | Disability | | WOMAC | 88/80 | 0.259 (0.155) | 1 |
| | | | | | ASES | 88/80 | 0.209 (0.155) | 2 |
| | | | | | SF-36 (PCS) | 88/80 | −0.009 (0.155) | 3 |
Kitay et al.
2009 | Osteoarthritis and Cartilage | Vibrations, CPM, and heat versus sham device | 71 | Pain | Adequate | WOMAC | 24/32 | 0.984 (0.284) | 1 |
| | | | | | VAS (knee) | 24/32 | 0.984 (0.284) | 1 |
Mazières et al.
2007 | Ann. Rheum. Dis. | Chondroitin sulphate versus placebo | 307 | Pain | Unclear | VAS (activity) | 139/140 | 0.260 (0.120) | 1 |
| | | | | | VAS (rest) | 139/140 | 0.092 (0.120) | 2 |
McCarthy et al.
2004 | Rheumatology | Class-based versus home-based exercise | 214 | Pain | Unclear | WOMAC | 111/103 | 0.321 (0.138) | 2 |
| | | | | | VAS (walking) | 111/103 | 0.836 (0.143) | 1 |
Moseley et al.
2002 | N. Engl. J. Med. | Arthroscopic debridement versus placebo | 119 | Pain | Unclear | Knee specific | | | |
| | | | | | Pain scale | 53/55 | 0.010 (0.232) | 3 |
| | | | | | AIMS (pain) | 53/55 | −0.072 (0.224) | 2 |
| | | | | | SF-36 (BP) | 52/55 | 0.114 (0.194) | 1 |
| | Arthroscopic lavage versus placebo | 121 | Pain | Unclear | Knee specific | | | |
| | | | | | Pain scale | 55/55 | 0.110 (0.236) | 2 |
| | | | | | AIMS (pain) | 56/55 | −0.200 (0.223) | 1 |
| | | | | | SF-36 (BP) | 57/55 | 0.090 (0.189) | 3 |
Neustadt et al.
2005 | J. Rheumatol. | Hyalerone four times a week versus control | 251 | Pain | Unclear | WOMAC | 115/114 | 0.098 (0.162) | 2 |
| | | | | | VAS (activity) | 104/100 | 0.158 (0.172) | 1 |
| | Hyalerone three times a week versus control | 242 | Pain | Unclear | WOMAC | 107/114 | −0.028 (0.164) | 2 |
| | | | | | VAS (activity) | 90/100 | 0.030 (0.176) | 1 |
Niethard et al.
2005 | J. Rheumatol. | Diclofena versus placebo | 238 | Pain | Unclear | WOMAC | 117/120 | 0.363 (0.131) | 1 |
| | | | | | VAS (activity) | 117/119 | 0.360 (0.131) | 2 |
Nuñez et al.
2006 | Osteoarthritis and Cartilage | Education programme versus control | 100 | Pain | Unclear | WOMAC | 43/37 | 0.980 (0.237) | 1 |
| | | | | | SF-36 (BP) | 43/37 | 0.605 (0.229) | 2 |
| | | | Disability | | WOMAC | 43/37 | 0.742 (0.232) | 1 |
| | | | | | SF-36 (PF) | 43/37 | 0.576 (0.229) | 2 |
J. Petrella and M. Petrella
2006 | Arch. Intern. Med. | Massage versus control | 74 | Pain | Adequate | WOMAC | 34/34 | 0.948 (0.256) | 1 |
| | | | | | VAS (knee) | 34/34 | 0.872 (0.254) | 2 |
Petrella et al.
2006 | J. Rheumatol. | Hyaleron versuscontrol | 106 | Pain | Inadequate | WOMAC | 53/53 | 0.092 (0.194) | 1 |
| | | | | | VAS (activity) | 53/53 | −0.040 (0.194) | 2 |
| | | | | | VAS (walking) | 53/53 | 0.000 (0.194) | 3 |
| | | | Disability | Unclear | WOMAC | 53/53 | −0.147 (0.195) | 2 |
| | | | | | SF-36 (PF) | 53/53 | 0.084 (0.194) | 1 |
Petrella
2002 | Arch. Intern. Med. | Hyalerone + placebo versus control | 53 | Pain | Unclear | WOMAC | 25/28 | 0.190 (0.384) | 4 |
| | | | | | VAS (activity) | 25/28 | 0.890 (0.398) | 1 |
| | | | | | VAS (rest) | 25/28 | −0.539 (0.389) | 3 |
| | | | | | VAS (walking) | 25/28 | 0.623 (0.391) | 2 |
| | Hyalerone + NSAID versuscontrol | 57 | Pain | Unclear | WOMAC | 29/28 | 0.238 (0.377) | 4 |
| | | | | | VAS (activity) | 29/28 | 0.501 (0.381) | 2 |
| | | | | | VAS (rest) | 29/28 | 0.383 (0.379) | 3 |
| | NSAID + saline versus control | 54 | Pain | Unclear | VAS (walking) | 29/28 | 1.268 (0.403) | 1 |
| | | | | | WOMAC | 26/28 | 0.336 (0.384) | 3 |
| | | | | | VAS (activity) | 26/28 | 1.622 (0.428) | 1 |
| | | | | | VAS (rest) | 26/28 | 0.173 (0.382) | 4 |
| | | | | | VAS (walking) | 26/28 | 1.154 (0.406) | 2 |
Pham et al.
2004 | Ann. Rheum. Dis. | Hyalerone versus control | 206 | Pain | Unclear | VAS (knee) | 131/85 | −0.035 (0.177) | 2 |
| | | | | | Painful days | 131/85 | −0.078 (0.177) | 1 |
| | Diacerein versus control | 170 | Pain | Unclear | VAS (knee) | 85/85 | −0.023 (0.188) | 2 |
| | | | | | Painful days | 85/85 | −0.027 (0.188) | 1 |
Ravaud et al.
2009 | BMJ | Standardised consultation versus usual care | 327 | Disability | Unclear | WOMAC | 146/181 | 0.260 (0.112) | 2 |
| | | | | | SF-12 (PCS) | 129/147 | 0.361 (0.122) | 1 |
Raynauld et al.
2003 | Arthritis Rheum. | Triamcinolone versus saline (control) | 68 | Pain | Unclear | WOMAC | 33/33 | 0.307 (0.248) | 2 |
| | | | | | VAS (knee) | 33/33 | 0.672 (0.253) | 1 |
Raynauld et al.
2002 | Osteoarthritis and Cartilage | Hylan G-F 20 versus Control | 255 | Disability | Unclear | WOMAC | 124/107 | 0.668 (0.136) | 1 |
| | | | | | SF-36 (PCS) | 124/107 | 0.553 (0.134) | 2 |
Rodrigues et al.
2008 | Arthritis Rheum. | Medial-wedge insole versus neutral insole | 30 | Pain | Adequate | VAS (activity) | 16/14 | 1.337 (0.405) | 1 |
| | | | | | VAS (rest) | 16/14 | 0.899 (0.384) | 2 |
| | | | | | VAS (night) | 16/14 | 0.802 (0.380) | 3 |
Rooks et al.
2006 | Arthritis Rheum | Preoperative exercise versus control | 45 | Pain | Unclear | WOMAC | 14/15 | 0.220 (0.373) | 2 |
| | | | | | SF-36 (BP) | 14/15 | −0.322 (0.374) | 1 |
| | | | Disability | | WOMAC | 14/15 | 0.034 (0.372) | 2 |
| | | | | | SF-36 (PF) | 14/15 | −0.391 (0.375) | 1 |
Sengupta et al.
2008 | Arthritis Res. Ther. | 5-Loxin 250 mg versus control | 50 | Pain | Unclear | WOMAC | 23/23 | 1.292 (0.393) | 2 |
| | | | | | VAS (knee) | 23/23 | 2.463 (0.467) | 1 |
| | 5-Loxin 100 mg versus control | 50 | Pain | Unclear | WOMAC | 24/23 | 1.039 (0.379) | 1 |
| | | | | | VAS (knee) | 24/23 | 1.918 (0.425) | 2 |
Song et al.
2009 | Ann. Rheum. Dis. | Icatibant 2000 μg versus control | 29 | Pain | Unclear | VAS (activity) | 14/15 | 0.492 (0.459) | 1 |
| | | | | | VAS (rest) | 14/15 | 0.391 (0.456) | 2 |
| | Icatibant 500 μg versus control | 27 | Pain | Unclear | VAS (activity) | 12/15 | 0.411 (0.470) | 1 |
| | | | | | VAS (rest) | 12/15 | 0.391 (0.470) | 2 |
Tannenbaum et al.
2004 | Ann. Rheum. Dis. | Lumiracoxib 400 mg versus placebo | 734 | Pain | Unclear | WOMAC | 491/243 | 0.211 (0.132) | 2 |
| | | | | | VAS (knee) | 491/243 | 0.307 (0.132) | 1 |
| | Lumiracoxib 200 mg versus placebo | 730 | Pain | Unclear | WOMAC | 487/243 | 0.189 (0.132) | 2 |
| | | | | | VAS (knee) | 487/243 | 0.236 (0.132) | 1 |
| | Celecoxib versus placebo | 724 | Pain | Unclear | WOMAC | 481/243 | 0.184 (0.132) | 2 |
| | | | | | VAS (knee) | 481/243 | 0.217 (0.132) | 1 |
Trnavský et al.
2004 | J. Rheumatol. | Ibuprofen versus placebo | 50 | Pain | Unclear | VAS (walking) | 25/25 | 1.739 (0.332) | 1 |
| | | | | | VAS (rest) | 25/25 | 0.932 (0.298) | 2 |
| | | | | | VAS (knee) | 25/25 | 0.786 (0.294) | 3 |
Vas et al.
2004 | BMJ | Acupuncture versus control | 97 | Pain | Unclear | WOMAC | 48/49 | 1.109 (0.218) | 2 |
| | | | | | VAS (knee) | 48/49 | 1.249 (0.222) | 1 |
Wang et al.
2009 | Arthritis Rheum. | Tai chi versus control | 40 | Pain | Adequate | WOMAC | 20/20 | 0.456 (0.320) | 1 |
| | | | | | VAS (knee) | 20/20 | 0.015 (0.316) | 2 |
| | | 40 | Disability | Adequate | WOMAC | 20/20 | 0.356 (0.319) | 2 |
| | | | | | SF-36 (PCS) | 20/20 | 0.820 (0.329) | 1 |
Witt et al.
2005 | Lancet | Acupuncture versus minimal acupuncture | 226 | Pain | Unclear | WOMAC | 149/75 | 0.150 (0.142) | 1 |
| | | | | | SES | 149/75 | 0.062 (0.142) | 2 |
| | | 226 | Disability | Unclear | WOMAC | 149/75 | 0.249 (0.142) | 1 |
| | | | | | SF-36 (PCS) | 149/75 | 0.215 (0.142) | 3 |
| | | | | | PDI | 149/75 | 0.245 (0.142) | 2 |
Wittenberg et al.
2006 | Arthritis Rheum. | Lumiracoxib versus placebo | 219 | Pain | Unclear | WOMAC | 144/75 | 0.406 (0.185) | 2 |
| | | | | | VAS (activity) | 144/75 | 0.645 (0.186) | 1 |
| | Celecoxib versus placebo | 220 | Pain | Unclear | WOMAC | 145/75 | 0.396 (0.184) | 2 |
| | | | | | VAS (activity) | 145/75 | 0.525 (0.185) | 1 |
|
